Vera Therapeutics aligns with FDA on earlier atacicept Phase 3 eGFR read
Vera Therapeutics has reached agreement with the US Food and Drug Administration on a revised analysis plan that moves the key kidney-function readout from its ORIGIN 3 Phase 3 trial into the third quarter of 2026, roughly a year ahead of the previously communicated timeline. The Brisbane, California company said that, subject to a positive eGFR result, it intends to file a supplemental Biologics Licence Application for full approval in the fourth quarter of 2026, with a decision possible in 2027.
The announcement comes ahead of a 7 July 2026 PDUFA date for the existing Biologics Licence Application seeking accelerated approval of atacicept in adults with IgA nephropathy (IgAN) — a progressive autoimmune kidney disease in which aberrant immunoglobulin A deposits trigger chronic inflammation and, over time, loss of renal function.
The science and the regulatory logic
Atacicept is a soluble fusion protein built around the TACI receptor, which binds both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL). Blocking both cytokines simultaneously suppresses the B-cell-mediated autoantibody production thought to drive IgAN pathology. The drug carries FDA Breakthrough Therapy Designation for the indication.
The accelerated-approval pathway permits conditional marketing authorisation on the basis of a surrogate endpoint — in this case, proteinuria reduction — while a confirmatory trial collects definitive evidence of clinical benefit. The ORIGIN 3 interim analysis, reported earlier this year, met its primary endpoint with a statistically significant and clinically meaningful reduction in proteinuria at week 36. The eGFR readout — measuring actual change in kidney filtration capacity — represents the confirmatory hurdle required for full approval.
Vera said the revised timeline was informed by a National Kidney Foundation workshop attended by clinicians, researchers, regulators, and patient advocates, as well as by favourable eGFR trends observed through 96 weeks in the earlier ORIGIN Phase 2b study.
Market context and competitive landscape
IgAN has become one of the more actively contested segments in nephrology following years of unmet need. Calliditas Therapeutics received conditional approval in major markets for budesonide formulation Tarpeyo (nefecon) on the strength of proteinuria data, and RaQualia Pharma-partnered Omeros has advanced MASP-2 inhibitor narsoplimab in the same space. Separately, Novartis's iptacopan — targeting the complement pathway — received FDA approval in 2024 for paroxysmal nocturnal haemoglobinuria and has an IgAN programme ongoing.
Atacicept's dual-cytokine mechanism differentiates it from complement inhibitors and corticosteroid-based options, though head-to-head data against approved agents do not yet exist. The company's claim to best-in-class positioning rests on class-of-action uniqueness and a clinical dataset that now spans more than 1,500 patients across multiple autoimmune indications, including lupus nephritis.
Beyond IgAN, Vera is evaluating atacicept in anti-PLA2R positive primary membranous nephropathy and anti-nephrin positive focal segmental glomerulosclerosis and minimal change disease through its PIONEER trial, suggesting a broader renal immunology franchise strategy. A next-generation BAFF/APRIL fusion protein, VT-109, is also in early development under licence from Stanford University.
Investors will focus on two near-term catalysts: the accelerated-approval PDUFA decision on 7 July, and the Q3 2026 eGFR data release that will determine whether a full-approval filing proceeds on schedule. A negative or inconclusive eGFR result would complicate the regulatory picture and delay commercial normalisation of the product's label, making the forthcoming data readout the pivotal event for the programme.